Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (271-280 of 512) with videos related to

Pageof 52
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 26, 2021
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trialMariona Riudavets, Marie Naigeon, Matthieu Texier, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockersBoris Duchemann, Marie Naigeon, Edouard Auclin, et al.
BMJ Open|December 26, 2022
Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocolDavid Boulate, Marine Fidelle, Caroline Caramella, et al.
Clinical Lung Cancer|June 12, 2017
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung CancerBonnie Glisson, Benjamin Besse, Manuel Cobo Dols, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLCFilippo G Dall'Olio, Claudia Parisi, Laura Marcolin, et al.
Expert Review of Anticancer Therapy|July 11, 2022
Immunosenescence, inflammaging, and cancer immunotherapy efficacyJulieta E Rodriguez, Marie Naigeon, Vincent Goldschmidt, et al.
Lung Cancer (Amsterdam, Netherlands)|February 2, 2024
International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. proposals for improvement. A RYTHMIC/ITMIG studyThierry J Molina, Anja C Roden, Malgorzata Szolkowska, et al.
Annals of the Rheumatic Diseases|June 11, 2017
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatmentRakiba Belkhir, Sébastien Le Burel, Laetitia Dunogeant, et al.
Cancers|October 27, 2022
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI ScoreMonica Pierro, Capucine Baldini, Edouard Auclin, et al.
Cancer Treatment Reviews|July 20, 2025
De-escalation strategies with targeted therapies in non-small cell lung cancerMartina Bortolot, Jordi Remon, Paolo Bironzo, et al.
Pageof 52

Showing results (271-280 of 512) with videos related to

Sort By:
Pageof 52
Lung Cancer (Amsterdam, Netherlands)|December 26, 2021
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trialMariona Riudavets, Marie Naigeon, Matthieu Texier, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockersBoris Duchemann, Marie Naigeon, Edouard Auclin, et al.
BMJ Open|December 26, 2022
Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocolDavid Boulate, Marine Fidelle, Caroline Caramella, et al.
Clinical Lung Cancer|June 12, 2017
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung CancerBonnie Glisson, Benjamin Besse, Manuel Cobo Dols, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLCFilippo G Dall'Olio, Claudia Parisi, Laura Marcolin, et al.
Expert Review of Anticancer Therapy|July 11, 2022
Immunosenescence, inflammaging, and cancer immunotherapy efficacyJulieta E Rodriguez, Marie Naigeon, Vincent Goldschmidt, et al.
Lung Cancer (Amsterdam, Netherlands)|February 2, 2024
International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. proposals for improvement. A RYTHMIC/ITMIG studyThierry J Molina, Anja C Roden, Malgorzata Szolkowska, et al.
Annals of the Rheumatic Diseases|June 11, 2017
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatmentRakiba Belkhir, Sébastien Le Burel, Laetitia Dunogeant, et al.
Cancers|October 27, 2022
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI ScoreMonica Pierro, Capucine Baldini, Edouard Auclin, et al.
Cancer Treatment Reviews|July 20, 2025
De-escalation strategies with targeted therapies in non-small cell lung cancerMartina Bortolot, Jordi Remon, Paolo Bironzo, et al.
Pageof 52